Sanobiotec is the research and development company of Nativus Group that identifies, develops and produces cannabinoids and flavonoids. We focus on minor cannabinoids which have a vast potential but are neither available on the market nor sufficiently researched.
We focus on the quality of the compounds we produce to ensure that their stability, solubility, purity and bioavailability meets the strictest criteria of the pharmaceutical industry.
Headquartered in Vilnius, Lithuania, the company operates a state-of-the-art laboratory and develops proprietary technological solutions designed for production of natural and custom compounds. Sanobiotec is also engaged in scientific research projects investigating the potential of cannabinoid-based medications used for treatment of specific diseases.
Our scientific team consists of PhD and MS level chemists, engineers and researchers and is led by professor Edvinas Orentas.
We are also holders of the licence to conduct R&D activities with Schedule 1 substances.
What We Do
Sanobiotec is committed to state-of-the-art extraction, purification and synthesis of innovative compounds. Our facility is equipped with industry-leading supercritical CO2 extraction, distillation and chromatography equipment and is fully adapted for rapid development and production of any compound, natural or synthetic.
When it comes to synthesis, we can both modify an existing compound as well as create a new one. The combination of these two areas enables us to create custom formulations containing either natural or synthetic compounds or both.
In addition to constant quality assurance and control, our analytical lab identifies and quantifies intermediates, side products and impurities, and determines the structures of unknown compounds.